University of California San Francisco
Researchers recently identified a universal, essential biomarker for the childhood cancer neuroblastoma – and the biomarker could be a potential new target for treatment.
Neuroblastoma accounts for 15% of all pediatric cancer deaths and is the most common source of childhood tumors outside of brain cancer. The disease develops in early nerve tissue, usually in and around the adrenal glands, and typically affects children under age five. High-risk cases have a five-year survival rate of just 50%.